brexanolone IV
Selected indexed studies
- The Black Book of Psychotropic Dosing and Monitoring. (Psychopharmacol Bull, 2024) [PMID:38993656]
- Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. (Ann Pharmacother, 2020) [PMID:31476884]
- Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae. (ACS Med Chem Lett, 2023) [PMID:37849543]
_Worker-drafted node — pending editorial review._
Connections
brexanolone IV is a side effect of
Sources
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. (2020) pubmed
- Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae. (2023) pubmed
- Treating postpartum depression with brexanolone. (2020) pubmed
- [Rapid-acting antidepressants-neurobiological mechanisms of action]. (2022) pubmed
- A retrospective chart review study of patients treated in a hospital-based brexanolone program. (2025) pubmed
- Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions. (2024) pubmed
- [GABAergic approach of postpartum depression: A translational review of literature]. (2020) pubmed
- Global Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next Decade. (2026) pubmed
- Development of neuroactive steroids for the treatment of postpartum depression. (2022) pubmed